statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Buy Rating on Dianthus Therapeutics Supported by Promising MMN Treatment Data and Market Potential

Dianthus Therapeutics (DNTH Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Rami Katkhuda...

What 5 Analyst Ratings Have To Say About Dianthus Therapeutics

Dianthus Therapeutics (DNTH, $29.67) Aroon Indicator entered an Uptrend on April 01, 2024.

Over the last three days, A.I.dvisor has detected that DNTH's AroonUp green line (see chart) is above 70, while the AroonDown red line is below 30. When the green line goes above 70 while the red...

Dianthus Therapeutics (DNTH, $30) Aroon Indicator entered an Uptrend on March 28, 2024.

Dianthus Therapeutics (DNTH, $30.51) RSI Indicator left the overbought zone on March 27, 2024

This is a signal that DNTH's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...

Dianthus Therapeutics (DNTH, $30.51) Aroon Indicator entered an Uptrend on March 27, 2024.

The volume for Dianthus Therapeutics stock increased for one day, resulting in a record-breaking daily growth of 213% of the 65-Day Volume Moving Average

DNTH's total volume now sits at 396.9K. The +1.19% price change was insignificant, leaving IBM's price at $31.36...

Dianthus Therapeutics Reaches Analyst Target Price

In recent trading, shares of Dianthus Therapeutics Inc (DNTH) have crossed above the average analyst 12-month target price of 31.80, changing hands for 31.94/share. When a stock reaches...

Dianthus Therapeutics (NASDAQ:DNTH) PT Raised to $39.00 at Jefferies Financial Group

Dianthus Therapeutics (NASDAQ:DNTH  Get Free Report) had its target price increased by equities researchers at Jefferies Financial Group from $22.00 to $39.00 in a research note issued to...

Dianthus Therapeutics' High-Stakes Gamble: Navigating Regulatory Risks and Supplier Challenges in Novel Drug Delivery

Dianthus Therapeutics, Inc. (DNTH) has disclosed a new risk, in the Regulation category. Dianthus Therapeutics, Inc. faces significant business ris...

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company. It designs and delivers novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company was founded on June 17, 2015 and is headquartered in New York, NY.

Volume	237,145.00
52-Wk High	$33.77
52-Wk Low	$6.58

DNTH Dianthus Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals